We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Diabetic Biomarkers Concordance Compared in South African Blacks

By LabMedica International staff writers
Posted on 28 Jun 2021
Print article
Image: The D-10 Hemoglobin Testing System provides comprehensive, automated hemoglobin testing in a compact footprint, combining HbA1c and HbA2/F/A1c testing on a single platform (Photo courtesy of Bio-Rad)
Image: The D-10 Hemoglobin Testing System provides comprehensive, automated hemoglobin testing in a compact footprint, combining HbA1c and HbA2/F/A1c testing on a single platform (Photo courtesy of Bio-Rad)
Sub-Saharan Africa is projected to experience a significant increase in the prevalence of diabetes mellitus by in the near future and accurate, comparable prevalence estimates will be essential to planning and monitoring by public health authorities.

Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.

A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.

Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).

The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.

The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.

Related Links:
University of the Witwatersrand
Bio-Rad Laboratories
Siemens Healthineers

Gold Supplier
Benchtop Auto Sample Transfer Processor
Silver Supplier
Automated Nucleic Acid Extractor
Gold Supplier
Automated Immune Analyzer
UNION Immune Analyzer
Silver Supplier
Automated Body Fluid Cell Count Control
Cell-Chex Auto

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.